AstraZeneca Crestor delay
Executive Summary
AstraZeneca expects an "approvable" letter for cholesterol agent Crestor (rosuvastatin) at the end of June, consistent with a 12-month user fee deadline, rather than original 10-month expectation. FDA is seeking data and analyses "to support the use of Crestor at higher doses," company says. The 80 mg dose was associated with rhabdomyolysis in Phase III trials (1"The Pink Sheet" Feb. 4, p. 25). The launch will be delayed beyond the third quarter...
You may also be interested in...
AstraZeneca Crestor 80 Mg Dose Would Have Low Demand, CEO Suggests
AstraZeneca expects that an 80 mg strength of Crestor, if approved, would constitute a small proportion of the product's sales
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.